Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as a tablet for oral use. It is prescribed for severe psoriasis, psoriatic erythroderma, and other keratinization disorders in adults. GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason is a retinoid used in the management of disorders characterized by abnormal keratinocyte proliferation and differentiation. - Severe psoriasis: reduces plaque formation, scaling and erythema. - Psoriatic erythroderma: helps control extensive skin inflammation and desquamation. - Other keratinization disorders: normalizes epidermal cell turnover and improves skin appearance.

Acitretin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dry skin and mucous membranes - Cheilitis (cracked lips) - Hair thinning or loss - Elevated liver enzymes - Hyperlipidaemia - Headache

Serious or Rare Side Effects: - Severe hepatic injury - Pancreatitis - Pseudotumour cerebri (intracranial hypertension) - Major depression or suicidal ideation - Severe hypertriglyceridaemia - Bone demineralisation or fractures

Before initiating therapy, clinicians should assess several safety parameters. - Pregnancy: contraindicated due to high teratogenic risk; ensure effective contraception. - Contraception: maintain dual‑method contraception for at least 3 years after discontinuation. - Liver function: obtain baseline tests and monitor periodically. - Lipid profile: check fasting lipids before start and during treatment. - Vision: monitor for symptoms of intracranial hypertension such as headache or visual changes. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Acitretin interacts with several medicines that may alter its safety or efficacy.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive retinoid toxicity. - Systemic corticosteroids: may reduce therapeutic response. - Warfarin: potential alteration of INR. - Other retinoids (e.g., isotretinoin): cumulative teratogenic and toxicity risk.

Moderate Interactions (Monitor Closely): - Methotrexate: heightened hepatic toxicity. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Statins: monitor liver enzymes. - Lipid‑lowering agents (fibrates): may exacerbate hyperlipidaemia. - Antifungal azoles (e.g., ketoconazole): can affect drug metabolism.